Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...